Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Legend Biotech (LEGN) EBIT (2019 - 2025)

Historic EBIT for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to -$43.5 million.

  • Legend Biotech's EBIT rose 3823.98% to -$43.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $138.2 billion, marking a year-over-year increase of 19893.44%. This contributed to the annual value of -$146.9 billion for FY2024, which is 5643.92% down from last year.
  • Per Legend Biotech's latest filing, its EBIT stood at -$43.5 million for Q3 2025, which was up 3823.98% from $337.9 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's EBIT registered a high of $137.6 billion during Q4 2024, and its lowest value of -$13.4 billion during Q1 2021.
  • Over the past 5 years, Legend Biotech's median EBIT value was $125.5 million (recorded in 2023), while the average stood at $9.1 billion.
  • Its EBIT has fluctuated over the past 5 years, first tumbled by 2385028.91% in 2021, then soared by 4181157.14% in 2023.
  • Quarter analysis of 5 years shows Legend Biotech's EBIT stood at $89.8 million in 2021, then grew by 21.62% to $109.2 million in 2022, then surged by 41811.57% to $45.8 billion in 2023, then skyrocketed by 200.51% to $137.6 billion in 2024, then plummeted by 100.03% to -$43.5 million in 2025.
  • Its EBIT stands at -$43.5 million for Q3 2025, versus $337.9 million for Q2 2025 and $287.5 million for Q1 2025.